X

Trial Profile

Double blind placebo controlled dose ranging study of the efficacy and safety of SSR149744C [Celivarone] 300 or 600mg for the conversion of atrial fibrillation/flutter.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 May 2012

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Celivarone (Primary)
Indications Atrial fibrillation; Atrial flutter
Focus Therapeutic Use
Acronyms CORYFEE

Most Recent Events

22 Dec 2008 Actual end date (Apr 2006) added as reported by ClinicalTrials.gov.
22 Dec 2008 Planned number of patients changed from 141 to 150 as reported by ClinicalTrials.gov.
05 Oct 2006 Status change

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com